Standard Biotools (LAB) Receivables - Net (2016 - 2025)
Standard Biotools (LAB) has disclosed Receivables - Net for 16 consecutive years, with $13.9 million as the latest value for Q3 2025.
- On a quarterly basis, Receivables - Net fell 60.57% to $13.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $13.9 million, a 60.57% decrease, with the full-year FY2024 number at $15.0 million, changed N/A from a year prior.
- Receivables - Net was $13.9 million for Q3 2025 at Standard Biotools, down from $15.0 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $36.0 million in Q1 2024 to a low of $10.9 million in Q2 2022.
- A 5-year average of $19.6 million and a median of $15.5 million in 2021 define the central range for Receivables - Net.
- Peak YoY movement for Receivables - Net: skyrocketed 148.29% in 2024, then tumbled 60.57% in 2025.
- Standard Biotools' Receivables - Net stood at $18.3 million in 2021, then decreased by 5.68% to $17.3 million in 2022, then fell by 4.17% to $16.6 million in 2023, then decreased by 9.41% to $15.0 million in 2024, then dropped by 7.12% to $13.9 million in 2025.
- Per Business Quant, the three most recent readings for LAB's Receivables - Net are $13.9 million (Q3 2025), $15.0 million (Q2 2025), and $35.5 million (Q1 2025).